GovChime
Notice ID: a4b6adf5a21b4771bdf4eea1010ca0aaCombined Synopsis/Solicitation

Custom Monospecific high-affinity IgG antibody production in rabbits for 15 custom synthesized immunograde peptides from 15 selected proteins of interest

Archived on October 3, 2020. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
10:00 AM UTC−04:00
Posted
September 9, 2020
Notice type
Combined Synopsis/Solicitation
Set-aside
Total Small Business Set-Aside (FAR 19.5)
NAICS
325413: In-Vitro Diagnostic Substance Manufacturing
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH NIAID
Place of performance
Rockville, MD, 20852
Last updated
Apr 29, 2026

Identifiers

Solicitation number
RFQ-NIAID-2039389
Notice ID
a4b6adf5a21b4771bdf4eea1010ca0aa

Description

This notice is a combined synopsis/solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 Streamlined Procedures for Evaluation and solicitation for commercial Items, as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. The Solicitation number is RFQ-NIAID-2039389 and the solicitation is issued as a Request for Quotes (RFQ). This acquisition will be processed under FAR Part 13 Simplified Acquisition Procedures (SAP). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2020-07, Effective 08/31/2020. The North American Industry Classification System (NAICS) code for this procurement is 325413, In-Vitro Diagnostic Substance Manufacturing, with a small business size standard size of 1250 employees. This requirement is set-aside for small business. Project Background: The laboratory of Malaria and Vector Research of NIAID is seeking custom Monospecific high-affinity IgG antibody production in rabbits for 15 custom synthesized immunograde peptides from 15 selected proteins of interest. The interaction of Plasmodium sporozoites with the human blood and the mosquito hemolymph and tissues are essential for the parasite to complete development and transmission however, the molecular identity of such interactions is still poorly understood. This project aims to identify interactions of the malaria parasite with the mosquito vector by characterizing the interactome between malaria sporozoite surface proteins, with mosquito saliva proteins. The proteins identified from the parasite and the mosquito, will be evaluated for their role during malaria transmission. Through proteomic analysis, we have identified 15 mosquito proteins with potential relevant role during transmission of the malaria parasite. Requirement: Please see attachment for the list of products and minimum specification needed. Place of Performance: 12735 Twinbrook Parkway, Rockville, MD 20852 Delivery: 30 days ARO *Include list specifications with quote *Include Animal Assurance #/documentation *Include your DUNS number on quote *Include response to FAR 52.204-26 and 52.204-24 and return with quote Submission shall be received not later than 10:00 a.m. EST, September 18, 2020. ALL OFFERORS MUST ALSO COMPLETE AND SIGN THE ATTACHED CERTIFICATION (VENDOR CERTIFICATION) The government intends to award a firm fixed price purchase order to the responsible contractor as a result of this RFQ that will include the terms and conditions set forth herein. The award will be based on the following; price, capability to meet the requirements, delivery and the best value to the government. The following FAR provisions apply to this acquisition: FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Aug 2020) FAR 52.204-26 Covered Telecommunications Equipment or Services-Representation (Dec 2019) FAR 52.212-1 Instructions to Offerors Commercial Items (Jun 2020) FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (Jun 2020) Offerors must complete annual representations and certifications on-line at http://www.sam.gov/ in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items (Please ensure 52.209-2 -- Prohibition on Contracting with Inverted Domestic Corporations--Representation. (Nov 2015) is updated in your SAM record) FAR 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements Representation (Jan 2017) The following FAR contract clauses apply to this acquisition: FAR 52-212-4 Contract Terms and Conditions Commercial Items (Oct 2018) FAR 52-212-5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (Aug 2020)*The applicable subparagraphs of FAR52.212-5 are included in the attachment to this posting. FAR 52.203-19 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements (Jan 2017) FAR 52.204-25 Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment (Aug 2020) FAR 52.232-40 Providing Accelerated Payments to Small Business Subcontractors (Dec 2013) FAR 52.204-19 Incorporation by Reference of Representations and Certifications (Dec 2014) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (Dec 2015) By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the System for Award Management (SAM) database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation (www.sam.gov). Copies of the above-referenced provisions and clauses are available from http://www.acquisition.gov & http: //www.hhs.gov/regulation/index.html or, upon request, either by telephone or fax. Offers may be mailed, e-mailed or faxed to Ms. Skye Duffner, (E-Mail/ skye.duffner@nih.gov 406-802-6092). Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f) (Oct 2018) All responsible sources may submit an offer that will be considered by this Agency. Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Ms. Skye Duffner at skye.duffner@nih.gov.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:RFQ-NIAID-2039389
  1. Combined Synopsis
  1. Combined SynopsisCurrentSep 9, 2020

    Custom Monospecific high-affinity IgG antibody production in rabbits for 15 custom synthesized immunograde peptides from 15 selected proteins of interest

    Notice a4b6adf5a21b4771bdf4eea1010ca0aa on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Please see attached Combined Synopsis/Solicitation. See attached estimated quantities and Questions and Answers.
-Combined Synopsis11/18/2026
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00027. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to Integrated DNA Technologies, Inc. (IDT), 1710 Commercial Park, Coralville, IA 52241, for custom-designed ArcherDX VariantPlex Next-Generation Sequencing (NGS) target-enrichment library preparation kits. Integrated DNA Technologies, Inc. is the sole owner, manufacturer, and distributor of the proprietary ArcherDX VariantPlex Anchored Multiplex PCR (AMP) chemistry, which has been utilized by the NHLBI Hematology Branch since 2019 to perform error-correcting sequencing (ECS) and is required to maintain scientific continuity, prevent technical batch effects across longitudinal patient cohorts, and ensure compatibility with the laboratory¿s established Archer Analysis bioinformatics pipeline. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325413 (In-Vitro Diagnostic Substance Manufacturing) and the small business size standard is 1,250 employees. This requirement is not set aside for small business.
-Combined Synopsis11/05/2026
See attached Sources Sought Notice.
-Market Research10/28/2026
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements. The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year. Justification: Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S. Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo. Requirements: SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101) SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260) Period of performance/Date of Delivery: Within 30 days of award, or mutually agreed upon. Place of Performance or Delivery: Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
-Pre-Solicitation11/11/2026
(i)This is a combined synopsis/solicitation for commercial items prepared in accordancewith the format in FAR Subpart 12.6, as supplemented with additional information includedin this notice. This announcement constitutes the only solicitation; proposals are beingrequested, and a separate written solicitation will not be issued. (ii)The solicitation number is 75N98027Q00017. This solicitation is issued as a Notice ofIntent (NOI) for a non-competitive combined synopsis/solicitation to award a contract orpurchase order without providing for full and open competition (including brand-name, ifapplicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a purchase order on a non-competitive basis to Purdue University, Purdue Institute for Drug Discovery (DRUG), 575 Stadium Mall Drive, West Lafayette, IN 47907, for the synthesis, scale-up, and characterization of lead Spleen Tyrosine Kinase (SYK) inhibitors in support of the NIH Bench-to-Bedside study "Developing Red Cell-Specific Spleen Tyrosine Kinase (SYK) Inhibitors for Treating Sickle Cell Disease." Rationale for non-competitive award: The proposed acquisition is a continuation of project-specific medicinal chemistry work under the NIH Bench-to-Bedside study "Developing Red Cell-Specific Spleen Tyrosine Kinase (SYK) Inhibitors for Treating Sickle Cell Disease." Dr. Philip S. Low's laboratory at Purdue University is the identified extramural medicinal chemistry collaborator for this project and has performed the prior design and synthesis work associated with the SYK inhibitor candidates being advanced under the study. The Year 1 requirement is specifically for the synthesis, scale-up, and characterization of lead SYK inhibitors S1115 and S1213 for subsequent biological evaluation by NIH investigators. Purdue possesses the project-specific knowledge and experience associated with these compounds. Use of another source would require duplication of prior research before the source could continue the current effort, resulting in delay and technical risk. Based on these circumstances, Purdue University is the only source reasonably available to perform this specific Year 1 requirement. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325411, Medicinal and Botanical Manufacturing, and the small business size standard is 1,250 employees. This requirement is not set aside for small business.
-Combined Synopsis11/04/2026

Additional Details

Solicitation Number

RFQ-NIAID-2039389

Archive Date

Oct 3, 2020

Office Address

BETHESDA, MD, 20892